Compare HP & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HP | EWTX |
|---|---|---|
| Founded | 1920 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.5B |
| IPO Year | N/A | 2021 |
| Metric | HP | EWTX |
|---|---|---|
| Price | $32.40 | $26.92 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 8 |
| Target Price | $30.27 | ★ $34.13 |
| AVG Volume (30 Days) | 1.4M | ★ 1.7M |
| Earning Date | 02-04-2026 | 03-02-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,746,013,000.00 | N/A |
| Revenue This Year | $9.18 | N/A |
| Revenue Next Year | $3.91 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 35.89 | N/A |
| 52 Week Low | $14.65 | $10.60 |
| 52 Week High | $37.30 | $30.48 |
| Indicator | HP | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 67.60 | 59.20 |
| Support Level | $31.40 | $23.57 |
| Resistance Level | $32.97 | $28.29 |
| Average True Range (ATR) | 1.20 | 1.47 |
| MACD | 0.22 | 0.22 |
| Stochastic Oscillator | 89.87 | 79.84 |
Helmerich & Payne Inc provides performance-driven drilling solutions and technologies to make hydrocarbon recovery safer and more economical for oil and gas exploration and production companies. Focusing on the drilling segment, its technology services develop and commercialize solutions that improve drilling efficiency, accuracy, and wellbore quality and placement. The company operates through North America Solutions, International Solutions, and Offshore Solutions segments. The North America segment runs a technologically advanced AC drive drilling rig fleet in the U.S., with a presence in shale and unconventional basins, while the Offshore Solutions segment, operating rigs on fixed-leg and floating platforms, generates the majority of revenue.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.